Burkitt Lymphoma is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Burkitt Lymphoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Burkitt Lymphoma compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Burkitt Lymphoma overview
Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in equatorial Africa, where it’s associated with the Epstein-Barr virus (EBV) infection and frequently affects children. It often presents as tumors in the jaw or facial bones. Sporadic Burkitt lymphoma is found worldwide, and is less associated with EBV but still affects children and adults. It can involve the abdomen, lymph nodes, bone marrow, or other organs. Immunodeficiency-associated Burkitt lymphoma occurs more commonly in individuals with weakened immune systems, such as those with HIV/AIDS or following organ transplantation. Burkitt lymphomas are characterized by rapid growth, often leading to the development of large tumors within a short period. Common symptoms include swelling of the lymph nodes, fever, night sweats, weight loss, and abdominal pain or swelling if organs in the abdomen are affected.
For a complete picture of PTSR and LoA scores for drugs in Burkitt Lymphoma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
